Chiusura precedente | 1,1700 |
Aperto | 1,0193 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 1,0193 - 1,0193 |
Intervallo di 52 settimane | 1,0193 - 1,0193 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 92,816M |
Beta (5 anni mensile) | 1,87 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,7710 |
Prossima data utili | 08 ago 2022 - 12 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
IRVINE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the first quarter 2022, ended March 31, 2022. First Quarter and Recent Highlights: Reported total revenue of $1.4 million in the first quarter of 2022, compared with $1.1 million in the first quarter
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisionsIRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it has completed development of its proprietary TheraSure™ Transplant Monitoring test for liver
IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m